Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates
Portfolio Pulse from
Blueprint Medicines (BPMC) reported a Q4 loss of $0.79 per share, missing the Zacks Consensus Estimate of a $0.70 loss. This is an improvement from the $1.82 loss per share a year ago.
February 13, 2025 | 2:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Blueprint Medicines reported a Q4 loss of $0.79 per share, which was worse than the expected $0.70 loss. Despite missing estimates, the loss is an improvement from the previous year's $1.82 per share.
The reported loss per share of $0.79 was worse than the expected $0.70, which is likely to negatively impact the stock price in the short term. However, the improvement from last year's $1.82 loss per share may mitigate some negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100